LMR Partners’s Vaxcyte PCVX Stock Holding History

LMR Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,000	Closed	-$378K	–	1577
2025 Q1	$378K	Buy	+10,000	New	+$800K	﹤0.01%	967

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

LMR Partners's PCVX Position: Q1 2025 in Review

LMR Partners sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 5,600 shares — an estimated $448K sold.

LMR Partners first reported a position in PCVX in Q4 2024 and held it in 1 quarter. The position peaked at $458K in Q4 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

LMR Partners reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 5,600 Vaxcyte shares in Q1 2025, an estimated $448K.
LMR Partners first reported a position in Vaxcyte in Q4 2024 and held it in 1 quarter.
LMR Partners's Vaxcyte position peaked at $458K in Q4 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.